How tyrosine kinase inhibitors impair metabolism and endocrine system function: A systematic updated review
Abstract
Tyrosine kinase inhibitors (TKIs) advent has deeply changed the outcome of chronic myeloid leukemia (CML) patients, with improved rates of response and overall survival. However, for this success some patients paid the price of a number of peculiar side effects, the so-called off-target side effects, specific for each one TKI. These effects are due to non-selective inhibition of other tyrosine kinase receptors, such as PDGFR, c-KIT, Src, VEGF. Consequences of this inhibition, some metabolic changes during the treatment with TKIs are reported. Aim of present review is to report metabolic changes and potential mechanisms involved in the pathogenesis related to imatinib, second (nilotinib and dasatinib) and third generation (bosutinib and ponatinib) TKIs.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
D and Q have side effects, including hematologic dysfunction, fluid retention, skin rash, and QT prolongation.
“Like all drugs, D and Q have side effects, including hematologic dysfunction, fluid retention, skin rash, and QT prolongation (Breccia et al., 2014).”
From The Achilles' heel of senescent cells: from transcriptome to senolytic drugs (2015) · cites this paper as Breccia et al., 2014
Cited by
Sorted by citations
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,562 · see citing works
“Like all drugs, D and Q have side effects, including hematologic dysfunction, fluid retention, skin rash, and QT prolongation (Breccia et al., 2014).”
BackgroundTherapeutic Potential of Senolytics in Cardiovascular Disease
Dookun, E., Passos, J. F., Arthur, H. M., & Richardson, G. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07075-w · Cited by 69 · see citing works
- Authors
- Breccia, M., Molica, M., & Alimena, G.
- Affiliations
- Sapienza University of Rome (IT)
- Corresponding author
- Breccia, Massimo
- Venue
- Leukemia Research
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 38
- Issue
- 12
- Pages
- 1392-1398
- ISSN
- 0145-2126 (ISSN-L)
- OpenAlex
- W2068126251
- Cited by
- 54
- References
- 0
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 7 · 2022: 3 · 2021: 6 · 2020: 4 · 2019: 3 · 2018: 6 · 2017: 8 · 2016: 5 · 2015: 6
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia Research (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Keywords
- tyrosine kinase inhibitors, chronic myeloid leukemia, metabolic changes, endocrine dysfunction, off-target effects, imatinib, nilotinib, dasatinib, bosutinib, ponatinib, PDGFR inhibition, c-kit inhibition, VEGF inhibition, Src family kinases, adverse drug reactions
- MeSH terms
- Endocrine System Diseases, Endocrine System, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Survival Rate, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
